Please login to the form below

Not currently logged in
Email:
Password:

NICE recommends Allergan eye implant

Allergan’s Ozurdex eye implant to treat macular oedema has been approved for use by the UK’s NHS in draft guidance from the National Institute for Health and Clinical Excellence

Allergan's Ozurdex (dexamethasone) eye implant to treat macular oedema has been approved for use by the UK's NHS in draft guidance from the National Institute for Health and Clinical Excellence (NICE).

The implant is approved in patients with macular oedema following central retinal vein occlusion (CRVO) or following branch retinal vein occlusion (BRVO) when treatment with laser photocoagulation has not been beneficial or is not suitable.

RVO is the blockage of a blood vessel in the retina so blood cannot drain out. This can lead to damage of an individual's eyesight.

Ozurdex works by suppressing inflammation in the eye, and is injected every six months.

Final guidance is due to be published in July 2011, with registered stakeholders able to appeal against the draft recommendations.

The announcement follows the news that Novartis' wet age-related macular degeneration treatment Lucentis (ranibizumab injection) has been approved for a new indication of vision loss due to macular oedema following RVO by the European Commission.

Ozurdex was approved by the European Medicines Agency (EMA) in 2010 as the first treatment authorised in Europe for the treatment for its current indication.

7th June 2011

From: Healthcare

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

The immunotherapy knowledge gap: keeping the patient at the heart of cancer treatment
Advances in cancer treatment are frequent, but how much do we actually understand about these new treatments?...
Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research
...